)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
XVIVO Perfusion (XVIVO) investor relations material
XVIVO Perfusion Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary23 Oct, 2025
Executive summary
Q3 2025 net sales were SEK 189 million, down 5% year-over-year, but organic growth excluding heart/US HART trial revenue was 6% in local currencies, with EBITDA margin recovering to 19% as destocking effects subsided.
Thoracic segment declined due to lower heart trial revenue, currency effects, and a softer U.S. lung market, while the Abdominal segment showed strong growth, especially in Europe.
Strategic investments included U.S. service partnerships to expand perfusionist capacity, commercial team reorganization, and increased surgical capacity.
Year-to-date net sales were SEK 586 million, with organic growth at 6% excluding trial revenue and 1% overall.
Operating cash flow was positive, with cash and cash equivalents at SEK 280 million at period end.
Financial highlights
Q3 net sales: SEK 189 million, organic growth +6% excluding trial revenue; gross margin 75% for Q3 and 74% YTD.
Adjusted EBIT margin: 9% in Q3; adjusted EBITDA margin: 19% in Q3 and 18% YTD.
Q3 net profit: SEK 4.3 million, EPS SEK 0.14, impacted by currency effects.
Cash position at period end: SEK 280 million, with SEK 120 million undrawn credit facility.
SEK/USD exchange rate negatively impacted EBITDA; a 9.50 rate in 2024 would have reduced EBITDA by SEK 20 million.
Outlook and guidance
Priority on obtaining CE mark for Heart in Europe, preparing U.S. heart regulatory file, and commercializing Heart Assist Transport.
Focus on increasing EVLP adoption, expanding service offerings, and establishing NRP procurement as a core U.S. service.
Long-term outlook remains positive, with machine perfusion and service models expected to drive significant growth.
Anticipates gradual recovery in global transplant growth through late 2025 and into 2026.
Regulatory milestones expected in 2026 for Heart Assist Transport in Europe and US PRESERVE study results.
Impact of heart perfusion solution CE delay?
Liver Assist US market pathway evaluation.
US lung market operational disruptions.
What specific evidence is needed for EU Heart CE-mark?
What are the trade-offs of a faster U.S. liver pathway?
How will new U.S. service strategy impact growth?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next XVIVO Perfusion earnings date
Q4 202527 Jan, 2026
Next XVIVO Perfusion earnings date
Q4 202527 Jan, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Xvivo Perfusion AB, a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation. The company's primary product line are the xVivo Perflex System and the xVivo S System that combine perfusion technology with a robust cryopreservation solution to maintain viability of cells outside the body. The xVivo Perflex System is used for functional organ preservation. The company is based in Gothenburg, Sweden.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage